Volume 29, Number 11—November 2023
Research
SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022
Table 1
Characteristic | No. (%) events | Incidence, % (95% CI) |
Incidence rate difference, % | ||
---|---|---|---|---|---|
Analytic cohort | PWH | PWOH | |||
Total observation period |
23,834 (100) |
50 (37–66) |
66 (57–77) |
50 (49–51) |
16 |
Timing of reinfection, by variant phase | |||||
Ancestral variant, 2020 Jan 1–Dec 31 | 866 (3.6) | 16 (9–26) | 30 (16–59) | 16 (15–17) | 14 |
Alpha and other pre-Delta variants, 2021 Jan 1–Jul 10 | 1,030 (4.3) | 6 (2–13) | 8 (4–16) | 6 (5–6) | 2 |
Delta variant, 2021 Jul 11–Dec 18 | 3,039 (12.8) | 11 (5–19) | 17 (12–25) | 11 (10–11) | 6 |
Omicron variant, 2021 Dec 19–2022 Mar 1 |
18,899 (79.3) |
40 (29–55) |
50 (42–60) |
40 (39–41) |
10 |
Timing of reinfection, by calendar quarter | |||||
2020 | |||||
Apr–Jun | 14 (0.1) | 2 (0–7) | 16 (1–209) | 2 (1–3) | 14 |
Jul–Sep | 268 (1.1) | 12 (6–21) | 30 (11–82) | 12 (10–13) | 18 |
Oct–Dec | 584 (2.5) | 11 (5–20) | 14 (5–37) | 11 (10–12) | 3 |
2021 | |||||
Jan–Mar | 549 (2.3) | 5 (2–12) | 5 (1–16) | 5 (4–6) | 0 |
Apr–Jun | 457 (1.9) | 3 (1–8) | 4 (1–12) | 3 (2–3) | 1 |
Jul–Sep | 721 (3.0) | 3 (1–9) | 9 (5–17) | 3 (2–-3) | 6 |
Oct–Dec | 9,477 (39.8) | 32 (22–45) | 42 (33–53) | 32 (31–32) | 10 |
2022 | |||||
Jan–Mar | 7,750 (32.5) | 20 (12–31) | 27 (21–35) | 20 (19–20) | 7 |
Apr–May | 4,014 (16.8) | 9 (4–17) | 9 (5–13) | 9 (8–9) | 0 |
*Incidence is given as percentage of cases per 1,000 person-years. PWH, persons with HIV; PWOH, persons without HIV.
Page created: September 06, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.